Medline (MDLN) vs Penumbra (PEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Medline is the larger company by market cap ($47.70 billion vs $12.46 billion), about 3.8 times the size. On valuation, Medline trades at a lower forward P/E (22.5x vs 51.6x for Penumbra). Penumbra converts more of its revenue into profit, with a net margin of 12.7% versus 4.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDLN | PEN |
|---|---|---|
| Share price | $35.45 | $316.35 |
| Market cap | $47.70B | $12.46B |
| 1-day change | -0.28% | -0.22% |
| YTD return | -15.60% | +1.75% |
| 1-year return | — | +27.03% |
| 5-year return | — | +18.15% |
| P/E ratio (TTM) | 88.63 | 77.73 |
| Forward P/E | 22.48 | 51.59 |
| EPS (TTM) | $0.40 | $4.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $28.43B | $1.40B |
| Revenue growth (YoY) | — | +17.50% |
| Net income (latest FY) | $1.16B | $177.69M |
| Gross margin | 26.44% | 67.14% |
| Operating margin | 7.78% | 13.48% |
| Net margin | 4.08% | 12.66% |
| 52-week high | $50.88 | $362.41 |
| 52-week low | $31.49 | $221.26 |
| Distance from 52-week high | -30.32% | -12.71% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +25.53% | +14.30% |
| Average volume | 7.59M | 343.03K |
| Shares outstanding | 877.35M | 39.39M |
| Employees | 45,000 | 4,700 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Medline is about 3.8 times larger than Penumbra by market value ($47.70B vs $12.46B).
- Penumbra is more profitable, keeping 12.7 cents of every revenue dollar as net income versus 4.1 cents for Medline.
About Medline
MDLN stock →Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally.
Health Care · Medical/Dental Instruments · 45,000 employees
About Penumbra
PEN stock →Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Health Care · Medical/Dental Instruments · 4,700 employees
MDLN vs PEN FAQ
Which is bigger, Medline or Penumbra?
Medline (MDLN) is larger, with a market capitalization of $47.70B compared with $12.46B for Penumbra (PEN).
Which has the lower P/E ratio, MDLN or PEN?
PEN has the lower trailing P/E at 77.7, versus 88.6 for MDLN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Medline and Penumbra in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.